TyrNovo's Corporate Majority Round

TyrNovo raised a round of funding on January 12, 2017. Investors include Kitov Pharmaceuticals Holdings.

TyrNovo is a developer of novel small molecules in the immuno-oncology therapeutic field, including NT219, a small molecule which has displayed potent anti-tumor effects and increased survival in vari…

Articles about TyrNovo's Corporate Majority Round: